A recent article from CBC News highlights a growing concern for many people who have used GLP-1 weight-loss medications such as semaglutide (Ozempic or Wegovy) or tirzepatide (Zepbound or Mounjaro): after stopping the treatment, many patients regain the weight they had lost, often within less than two years. Beyond the clinical implications, this raises a financial consideration as well: while a private sleeve gastrectomy costs about $18,000 for a durable, evidence-based solution, the same amount would cover 36–51 months (3 to just over 4 years) of continuous GLP-1 medication at $350–$500 per month, often with weight regain once the medication is stopped. This reality invites a closer look at long-term, sustainable options for managing weight.

GLP-1 medications work by influencing appetite and satiety, helping many people lose significant weight while on therapy. However, obesity is a chronic, relapsing condition. When the underlying biologic drivers of appetite and metabolism are unchanged, the body tends to return to its previous state once the pharmacologic influence is removed. Studies have shown that weight often returns steadily after stopping GLP-1 medications, and improvements in cardiovascular risk factors may also reverse.

It’s also important to consider the financial implications:

• At a monthly cost of roughly $350–$500 for GLP-1 weight-loss medication, $18,000 spent on drugs represents approximately 36–51 months (3 to just over 4 years) of continuous medication use.

• In contrast, a sleeve gastrectomy performed privately typically costs around $18,000 as a one-time procedure, providing a durable physiologic tool for long-term weight control.

For many patients who struggle with weight regain after medication discontinuation, bariatric surgery can be both a clinically and financially sensible long-term solution.

Access to bariatric surgery differs between the public and private healthcare systems:

• In many public programs, eligibility is still based on older criteria, often requiring higher BMIs and longer waiting times.

• Private bariatric programs often follow more up-to-date guidelines, allowing patients with lower BMIs or significant comorbidities to access surgery sooner.

This means that some patients who are not yet eligible in the public system may still benefit from private bariatric surgery, potentially preventing further complications related to obesity.

Unlike medications that only suppress appetite while taken, bariatric surgery produces anatomical and hormonal changes that alter hunger signals, energy balance, and metabolism. This can result in sustained weight loss and durable improvements in conditions like type 2 diabetes, hypertension, and sleep apnea.

Weight-loss medications have transformed obesity management and helped many patients achieve meaningful short-term results. Yet, the evidence shows that weight often returns after discontinuing GLP-1 medications, highlighting the chronic nature of obesity and the need for durable strategies.

For those who have tried medications and struggled with weight regain, private bariatric surgery offers a long-term, physiologically grounded solution, with the added benefit that private access may allow earlier intervention than public programs.